AKBA — Akebia Ther
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$0.97
+$0.02 (+2.52%)
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by John P. Butler MBA, based in 245 First Street, Cambridge, MA, United States, 02142, with about 194 employees. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Latest reported AKBA revenue for 2025-09-30 was $58.8M. Net income was $540.0K. Revenue was down 5.9% from 2025-06-30 to 2025-09-30. AKBA currently screens at market cap $260.1M.
Use this AKBA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AKBA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AKBA SEC filings page. Lician reads the product cache first so this HTML stays unique to Akebia Ther even when a live quote feed is slow.
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AKBA Key Statistics
Market Cap
$260.13M
Volume
8.12M
Previous Close
$0.91
Day Range
$0.87 – $0.91
EPS
-$0.33
Revenue
$160.18M
Net Income
-$69.41M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-17.7%
Profit Margin
-43.3%
Employees
194
AKBA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $160.18M | $194.62M | $292.48M | $213.58M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$69.41M | -$51.92M | -$92.56M | -$282.84M |
| EPS (Diluted) | -$0.33 | -$0.28 | -$0.52 | -$1.70 |
Total Assets
$220.67M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$51.87M
Operating Cash Flow
-$40.66M
Free Cash Flow
$0.00
Akebia Ther Company Information
- CEO, President & Director
- John P. Butler MBA
- Headquarters
- 245 First Street, Cambridge, MA, United States, 02142
- Website
- www.akebia.com
- Phone
- 617 871 2098
- IPO / Founded
- 2014-03-20
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic